Antagonistic CTLA-4 antibodies, such as ipilimumab, increase immune activation and are successfully used in tumor therapy [8, 9], whereas agonistic CTLA-4 fusion proteins, like commercially available belatacept and abatacept, act immunosuppressive. This evidence concerns the gene CTLA4 and neoplasm.